Drug Trial Radar · NCT04773353
Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Indian Women
Last checked: Nov 19, 2026Latest source record: Jan 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
220
Actual
Start
Dec 3, 2021
Primary completion
Dec 12, 2023
Study completion Dec 12, 2023
Sponsor
- Lead sponsor
- Ferring PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 21 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate non-inferiority of FE 999049 compared with GONAL-F with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation.
Conditions
- Infertility
Interventions
Follitropin Delta (FE 999049)Drug
FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. For participants with low AMH (\<15 pmol/L) the daily FE 999049 dose was 12 μg, irrespective of body weight. For participants with high AMH (≥15 pmol/L) the daily FE 999049 dose was on a continuous scale ranging from 0.19 to 0.10 μg/kg, i.e. dependent on actual AMH and body weight. The daily FE 999049 dose was fixed throughout the stimulation period and maximum allowed daily dose was 12 μg. Participants could be treated for a maximum of 20 days.
Follitropin Alfa (GONAL-F)Drug
GONAL-F was administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 450 IU. Participants could be treated for a maximum of 20 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ongoing pregnancy rateTime frame: 10-11 weeks after embryo transfer
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Ferring Investigational Site
Bangalore, India
Ferring Investigational Site
Kolhāpur, India
Ferring Investigational Site
New Delhi, India
Ferring Investigational Site
Ahmedabad, Gujarat, India
Ferring Investigational Site
Anand, Gujarat, India
Ferring Investigational Site
Nashik, Maharashtra, India
Ferring Investigational Site
Pune, Mumbai, India
Ferring Investigational Site
Varanasi, New Delhi, India
Ferring Investigational Site
Chennai, Tamil Nadu, India
Ferring Investigational Site
Coimbatore, Tamil Nadu, India
Ferring Investigational Site
Secunderabad, Telangana, India
Ferring Investigational Site
Lucknow, Uttar Pradesh, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.